PriceTargets.com logo

LON:SENS - Sensyne Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 336
  • Forecasted Upside: 129.35 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 146.50 As of 09/17/2021 05:18 PM ET
▼ -2.5 (-1.68%)

This chart shows the closing price for SENS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensyne Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SENS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SENS

Analyst Price Target is GBX 336
▲ +129.35% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sensyne Health in the last 3 months. The average price target is GBX 336, with a high forecast of GBX 349 and a low forecast of GBX 310. The average price target represents a 129.35% upside from the last price of GBX 146.50.

This chart shows the closing price for SENS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Sensyne Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2021Liberum CapitalReiterated RatingBuyGBX 310
5/27/2021Peel HuntReiterated RatingBuyGBX 349
5/27/2021Peel HuntReiterated RatingBuyGBX 349
5/24/2021Liberum CapitalReiterated RatingBuyGBX 310
5/7/2021Liberum CapitalReiterated RatingBuyGBX 310
2/9/2021Liberum CapitalReiterated RatingBuyGBX 310
11/2/2020Liberum CapitalReiterated RatingBuyGBX 260
7/2/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/20/2020Peel HuntReiterated RatingBuy
5/14/2020Peel HuntReiterated RatingBuy
5/14/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/20/2020Peel HuntReiterated RatingBuy
4/20/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/30/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/3/2020Liberum CapitalReiterated RatingBuy
3/3/2020Peel HuntReiterated RatingBuy
2/11/2020Peel HuntLower Price TargetBuyGBX 262 ➝ GBX 195
2/5/2020Peel HuntReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/21/2020Liberum CapitalReiterated RatingBuy
1/21/2020Peel HuntReiterated RatingBuy
1/10/2020Peel HuntReiterated RatingBuy
1/9/2020Liberum CapitalReiterated RatingBuy
12/23/2019Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/15/2019Peel HuntReiterated RatingBuy
11/15/2019Liberum CapitalReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
10/22/2019Peel HuntReiterated RatingBuy
10/22/2019Liberum CapitalReiterated RatingBuy
10/10/2019Peel HuntReiterated RatingBuyGBX 262
10/10/2019Peel HuntReiterated RatingBuyGBX 262
10/10/2019Liberum CapitalInitiated CoverageBuyGBX 260
10/4/2019Peel HuntReiterated RatingBuy
9/27/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
7/31/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/24/2019Peel HuntReiterated RatingBuy
6/12/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
4/30/2019Peel HuntReiterated RatingBuy
4/2/2019Peel HuntReiterated RatingBuy
3/27/2019Peel HuntReiterated RatingBuy
3/12/2019Peel HuntBoost Price TargetBuyGBX 261 ➝ GBX 262
1/28/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
12/6/2018Peel HuntReiterated RatingBuy
11/14/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/24/2018Peel HuntReiterated RatingBuy
10/16/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/26/2018Peel HuntInitiated CoverageBuyGBX 261
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sensyne Health logo
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Read More

Today's Range

Now: GBX 146.50
Low: 145
High: 150

50 Day Range

MA: GBX 148.09
Low: 140
High: 155

52 Week Range

Now: GBX 146.50
Low: 53.10
High: 190

Volume

103,877 shs

Average Volume

241,365 shs

Market Capitalization

£241.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensyne Health?

The following Wall Street analysts have issued research reports on Sensyne Health in the last year: Liberum Capital, Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for SENS.

What is the current price target for Sensyne Health?

3 Wall Street analysts have set twelve-month price targets for Sensyne Health in the last year. Their average twelve-month price target is GBX 336, suggesting a possible upside of 129.4%. Peel Hunt has the highest price target set, predicting SENS will reach GBX 349 in the next twelve months. Liberum Capital has the lowest price target set, forecasting a price of GBX 310 for Sensyne Health in the next year.
View the latest price targets for SENS.

What is the current consensus analyst rating for Sensyne Health?

Sensyne Health currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SENS will outperform the market and that investors should add to their positions of Sensyne Health.
View the latest ratings for SENS.

What other companies compete with Sensyne Health?

Other companies that are similar to Sensyne Health include Craneware, CloudMD Software & Services, Forian, kneat.com, Reliq Health Technologies, Vitalhub, Induction Healthcare Group, DIAGNOS, IQ-AI, CardioComm Solutions, ZoomMed, 1st Group, Alcidion Group, Binovi Technologies and Cann American.

How do I contact Sensyne Health's investor relations team?

The company's listed phone number is 44 3300 581845. The official website for Sensyne Health is www.sensynehealth.com.